^
Association details:
| Biomarker: | RYR1 mutation + PD-L1 overexpression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non–Small Cell Lung Cancer A Meta-analysis and Individual Patient–Level Analysis
Excerpt:
Notably, RYR1 or MGAM mutations were associated with concomitantly increased DCB (RYR1: DCB, 12 of 51 [24%]; NDB, 2 of 55 [4%]; P < .001; MGAM: DCB, 12 of 51 [24%]; NDB, 0 of 55; P < .001), a higher TMB (RYR1: high TMB, 12 of 53 [23%]; low TMB, 2 of 53 [38%]; P < .001; MGAM: high TMB, 9 of 53 [17%]; low TMB, 0 of 53; P < .001), and higher PD-L1 expression (RYR1: high PD-L1, 8 of 30 [27%]; low PD-L1, 6 of 85 [7%]; P < .001; MGAM: high PD-L1, 6 of 30 [20%]; low PD-L1, 5 of 85 [6%]; P < .001)...The predictive value of that combination needs to be prospectively validated in large-scale studies.
DOI:
10.1001/jamanetworkopen.2019.6879
Trial ID:
